HCM
HUTCHMED (China) Limited
Earnings and EPS analysis
- Stocks
- Healthcare
- NASDAQ: HCM
- Earnings
Relative Growth:
Rel. Growth:
31
Relative Strength:
Rel. Strength:
17
Relative Valuation:
Rel. Valuation:
86
Relative Profitability:
Rel. Profitability:
83
EPS in 2026 (TTM): $2.65
Last Report Period Date: Dec 31, 2025
Currently, HCM's current EPS stands at $2.65, according to the most recent financial reports. For the year 2025, HCM reported a per-share earnings of $2.65, which marks an increase compared to the EPS of $0.2 recorded in 2024.
HCM earnings history
Historical annual and quarterly earnings per share (EPS) data for HUTCHMED (China) Limited
EPS (TTM)
$2.65
In 2025, HUTCHMED (China) Limited's EPS was $2.65, an increase of 1,225% from $0.2 in 2024. For the twelve months ending December 2025, the EPS is $2.65. For the year 2024, the yearly earnings per share was $0.2, marking a decrease of 66.7% compared to 2023.
HCM earnings chart
HCM EPS growth history
Earnings per share growth rates over time
EPS growth YoY
1,225%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A
HCM Earnings Waterfall
Breakdown of revenue, profit and net income for HUTCHMED (China) Limited
HCM Earnings vs Peers
What are the earnings of HCM compared to its peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| HCM HUTCHMED (China) Limited | 4.15 | 1,225% | N/A | N/A |
| BMY Bristol Myers Squibb Co | 17.39 | 178.7% | 5.3% | N/A |
| PFE Pfizer Inc | 18.73 | -3.5% | -37.4% | -3.7% |
| NVS Novartis AG | 23.27 | 21.8% | 31.2% | 15.2% |
| AZN Astrazeneca plc | 25.23 | 45.4% | 46% | 22% |
| AMGN Amgen Inc | 25.97 | 88.1% | 5.6% | 2.9% |
| JNJ Johnson & Johnson | 30.17 | 90.6% | 17.7% | 14.8% |
| MRK Merck & Co Inc | 36.71 | 8% | 8.4% | 21.2% |
| LLY ELI LILLY & Co | 42.43 | 95.6% | 49.2% | 27.5% |
All data is based on quarterly TTM periods, unless otherwise specified.